Hakimeh Akbari - Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran
Hossein Forouzandeh - Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran
Tooraj Reza Mirshekari - Department of Pathology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
Seyed Adnan Kashfi - Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran
Mehdi Ghavamizadeh - Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran

Background & Objective: Breast cancer has a pivotal role in many deaths caused by malignancies. Epidermal growth factor receptor-۲ (EGFR-۲ or HER-۲) and estrogen receptor (ER) have immense predictive values as prognostic factors. Breast cancers that have steroid receptors and respond to hormone therapy show a better prognosis than cancers without steroid receptors. Materials & Methods: A retrospective cross-sectional study was performed on ۵۰۰ pathology blocks of women with breast cancer sent to the pathology department of Amir-al-Momenin medical and educational center, Gerash, Iran, from ۲۰۱۶ to ۲۰۱۹. Data were analyzed by SPSS software (Version-۱۶) via ANOVA test followed by Chi-square and t-tests. P-value <۰.۰۵ was considered as significant. Results: The utmost type of malignancy was invasive ductal carcinoma (IDC) at ۳۵.۰۳%. Among ER-positive patients ۵۹.۶۷% were HER-۲-positive. Nonetheless, among the PR-positive patients ۵۴.۷۴% were HER-۲-positive. ER-positive patients were correlated with p۵۳ receptor, distant metastasis and HER-۲ significantly (P<۰.۰۱). However, PR-positive patients just correlated with p۵۳ receptor significantly (P<۰.۰۱). Conclusion: Investigated samples were more ER-negative and less PR-positive compared to similar studies. Meanwhile, ER-positive patients were HER-۲-positive. Regarding the correlation with prognosis of breast cancer, especially in HER-۲-positive patients, there is a need to perform profound screening programs for HER-۲ in breast cancer patients, especially with histopathological characteristics of invasive ductal carcinoma.

Breast Cancer, HER-۲, P۵۳, Prevalence, Prognosis